Westwind Capital Raises Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Westwind Capital lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,662 shares of the company's stock after buying an additional 1,211 shares during the quarter. IDEXX Laboratories makes up 4.0% of Westwind Capital's holdings, making the stock its 11th largest position. Westwind Capital owned about 0.05% of IDEXX Laboratories worth $18,465,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC raised its position in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after acquiring an additional 60 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at about $36,000. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth about $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.11% of the company's stock.

Analysts Set New Price Targets

IDXX has been the topic of several research analyst reports. Barclays lowered their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Piper Sandler reiterated a "neutral" rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $539.63.

IDEXX Laboratories Trading Down 0.4 %

Shares of IDXX stock traded down $1.90 during trading hours on Tuesday, hitting $427.26. The company had a trading volume of 521,548 shares, compared to its average volume of 465,912. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The stock has a market capitalization of $34.99 billion, a PE ratio of 41.20, a price-to-earnings-growth ratio of 3.94 and a beta of 1.36. The company's fifty day moving average is $424.02 and its 200 day moving average is $461.79. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same period last year, the business posted $2.53 earnings per share. The company's quarterly revenue was up 6.6% on a year-over-year basis. Research analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.